A Randomized Phase II Trial of Consolidation Therapy Following CD19 CAR T Cell Treatment for Relapsed/Refractory Large B Cell Lymphoma or Grade IIIB Follicular Lymphoma

Sponsor:

SWOG

Sponsor Study ID:

S2114

CTO #:

103873

NCT Number:

NCT05633615

Phase:

II

Protocol Type:

Treatment

Age Group:

Adults

Disease Sites:

Non-Hodgkin's Lymphoma

Study Objectives:

To compare the progression-free survival in participants with relapsed/refractory large B-cell lymphoma or follicular lymphoma grade 3B with stable disease (SD) or partial remission (PR) on first imaging response by central review (day +30 PET/CT scan) after commercial CD19 CAR T-cell therapy who are randomized to receive each consolidation therapy versus those that receive no consolidation therapy (i.e. control). Specifically, to compare the PFS of 1) mosunetuzumab consolidation to no consolidation, 2) polatuzumab vedotin consolidation to no consolidation, 3) mosunetuzumab + polatuzumab vedotin to no consolidation

eConsent:

Not available

Study Documents:

Open Study Documents
(MUSC NetID required for document access)